generic speaker image
Craig Earle, MD - Canadian Partnership Against Cancer. Toronto, ON, CA

Craig Earle, MD Craig Earle, MD

Chief Executive Officer | Canadian Partnership Against Cancer

Toronto, ON, CANADA

Dr. Earle leads the transformation of Canada's cancer system as CEO of the Partnership, steward of the Canadian Strategy of Cancer Control






Headshot 1 loading image


Meet the Researchers - Dr. Craig Earle




Dr. Craig Earle joined the Partnership in 2017 and is currently Chief Executive Officer. In his previous role, Dr. Earle was Vice-President, Cancer Control, where he led programs and initiatives that deliver on the priorities and actions of the 2019-2019 Canadians Strategy for Cancer Control. Dr. Earle is also a medical oncologist specializing in gastrointestinal oncology at Sunnybrook’s Odette Cancer Centre, a Senior Scientist at ICES and a Professor of Medicine at the University of Toronto. He completed his medical training and Master of Science (epidemiology) at the University of Ottawa and a research fellowship at Harvard, followed by 10 years – 1998 to 2008 – at Harvard Medical School, Dana-Farber Cancer Institute, Brigham & Women’s Hospital and the Harvard School of Public Health in Boston, Massachusetts. Prior to joining the Partnership, he was Head of Clinical Translation at the Ontario Institute for Cancer Research. He is also a former Director of the Health Services Research Program for Cancer Care Ontario.

Areas of Expertise (4)

Pan-Canadian Cancer Control

Health Services Research

Gastrointestinal Cancers

Medical Oncology

Accomplishments (6)

Sunnybrook Health Sciences Centre Mentorship Award (professional)


Sunnybrook Health Sciences Centre's Department of Medicine - William J. Sibbald Faculty Mentorship Award

Society of General Internal Medicine Distinction (professional)


Society of General Internal Medicine (SGIM). (Distinction) Distinguished Professor of Cancer Research

Fellow of the American Society of Clinical Oncology (professional)


Fellow of the American Society of Clinical Oncology from the American Society of Clinical Oncology. (Distinction)

University of Toronto Quality Improvement Award (professional)


University of Toronto's Division of Medical Oncology - Quality Improvement Award

Ontario Institute for Cancer Research (OICR) Investigator Award (professional)


2013-2018: Awarded to Dr. Craig Earle. The program provides stable recruitment and retention funding for principal investigators in Ontario, further strengthening the province’s cancer research capacity.

Sunnybrook Health Sciences Centre Senior Investigator Award (professional)


Senior Investigator Award at Sunnybrook Health Sciences Centre (Research Award)

Education (3)

University of Ottawa: M.Sc., Epidemiology 1998

University of Ottawa: MD, Medicine 1990

University of Ottawa: B.Sc., Biochemistry 1989

Affiliations (5)

  • Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
  • Head, clinical translation, Ontario Institute for Cancer Research
  • Professor, department of medicine, University of Toronto
  • Senior scientist and cancer program leader, Institute for Clinical and Evaluative Sciences
  • Medical oncologist, gastrointestinal oncology, Sunnybrook Health Sciences Centre

Languages (1)

  • English

Media Appearances (2)

The dangers of smoking with cancer (video)

Breakfast Television Toronto  tv


See link to video This week is National Non-Smoking Week, and we're talking to VP of Cancer Control at the Partnership Against Cancer, Dr. Craig Earle, on the effects of smoking on people who have cancer.

Media Appearance Image

view more

Weighing the merits of ‘never-say-die’ oncology

National Post  print


Close to one in four patients studied received potentially aggressive care in their last month, it found. Care of all kinds in the last months of life generally costs the health-care system billions of dollars a year, other research has suggested. The oncologist who led the Ontario study, Dr. Craig Earle of Toronto's Sunnybrook Health Sciences Centre, said hospice beds and palliative services in patients' homes are often not available. He and other experts advocate new government spending on palliative care, designed to lessen pain and discomfort and address psychological and spiritual issues for patients whose illness can no longer be treated.

view more

Research Focus (1)

Health services research in cancer

Dr. Earle’s research program focuses on using administrative data to evaluate the accessibility, quality, costs and outcomes of care delivered to cancer patients and survivors.

Research Grants (3)

What is the impact of a provincial program to screen for symptoms on health service use?

Canadian Cancer Society Research Institute $193,417

Innovation Grant: 2016-2019

The prostate cancer program project in rapid development of novel diagnostic markers for early prostate cancer (PRONTO)

Prostate Cancer Canada $4,995,400

Movember Team Grant: 2014-2019

A population study of the toxicity and effectiveness of high-dose interferon for high-risk melanoma

Canadian Institutes of Health Research $360,993

Operating Grant: 2014-2017

Articles (6)

Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study

PLoS One

2017 The incidence of esophageal adenocarcinoma (EAC) is increasing worldwide and has overtaken squamous histology in occurrence. We studied the impact of socioeconomic status (SES) on EAC stage at diagnosis, receipt of treatment, and survival. A population-based retrospective cohort study was conducted using Ontario Cancer Registry-linked administrative health data.

view more

Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting

PLoS One

2017 Hepatocellular carcinoma (HCC) presentation is heterogeneous necessitating a variety of therapeutic interventions with varying efficacies and associated prognoses. Poor prognostic patients often undergo non-curative palliative interventions including transarterial chemoembolization (TACE), sorafenib, chemotherapy, or purely supportive care.

view more

Has Province-Wide Symptom Screening Changed Opioid Prescribing Rates in Older Patients With Cancer?

Journal of Oncology Practice

2017 Previous work in Ontario demonstrated that 33% of patients with cancer with severe pain did not receive opioids at the time of their pain assessment. With efforts to increase symptom screening and management since then, the objective of this study was to examine temporal trends in opioid prescribing.

view more

Family Perspectives on Aggressive Cancer Care

Journal of the American Medical Association (JAMA)

2016 Patients with advanced-stage cancer are receiving increasingly aggressive medical care near death, despite growing concerns that this reflects poor-quality care. The objective of this study was to assess the association of aggressive end-of-life care with bereaved family members' perceptions of the quality of end-of-life care and patients' goal attainment.

view more

Quality of care for comorbid conditions during the transition to survivorship: Differences between cancer survivors and non-cancer controls

Journal of Clinical Oncology

2013 Building on previous research documenting differences in preventive care quality between cancer survivors and noncancer controls, this study examines comorbid condition care.

view more

Geographic variation in physicians’ responses to a reimbursement change

New England Journal of Medicine (NEJM)

2011 Although much research has revealed U.S. geographic variation in the intensity of health care utilization and the level of Medicare spending,1 such variation in response to Medicare policy changes has received much less attention. This limitation has become more important in the face of the myriad Medicare-reimbursement changes included in the Patient Protection and Affordable Care Act (ACA). This study looked at the variation in geographic response to a major reform of Medicare's reimbursement system for physician-administered drugs (Part B), the vast majority of which are chemotherapy agents.

view more